Wells Fargo Downgrades Apellis Pharmaceuticals to Equal-Weight, Raises Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 62.5%

Neg 62.5% Neu 0% Pos 0%

Wells Fargo analyst Derek Archila downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Overweight to Equal-Weight and raises the price target from $26 to $41.